OxStem is a drug discovery company, spun-out from the University of Oxford in 2016, with the unique vision of developing small molecule therapeutics that augment repair mechanisms that already exist within the body. OxStem is developing drug candidates that can awaken endogenous cells to repair tissues affected by disease or injury to treat diseases such as Dementia, Heart Failure, Macular Degeneration (the leading cause of blindness in the developed world) and Oncology.
Who are we?
At Parkinson’s Concierge we want to promote Patient Engagement, Involved, and have the opportunity to accelerate the desperate need for a Cure.
It is now evident that to find a Cure for Parkinson’s everyone needs to be involved and partnering with each other.
At Parkinson’s Concierge we are becoming a voice for People with Parkinson’s.
We all live with Parkinson's.
We want to be involved in all aspects of finding a cure for Parkinson’s and believe it is the way forward to be the final link between Tech companies/ Pharma/Medical Industry Professionals.
Inclusion is required in the following areas
Involved with the strategic development of patient and professional relationships
Enable us to contribute to funding for clinical research trials for Parkinson’s
We have a particular interest in engaging with early detection/research companies
Connecting and communicating with stakeholders
Identifying key relationships between all business partnerships
We are Advocates of the Parkinson’s Movement
We sit on the Panel of Parkinson’s Steering Committees at various hospitals for research
Inclusion with clinical trials where Patients can be involved with execution through to completion by providing tech data (that is so desperately needed) from the people who live with Parkinson’s
What can we offer you?
Within our team we have people with expertise in the areas of drug development, clinical trial operations, and strategic planning, relationship management, awareness creation, & training
Our biggest USP is of course, we ALL have Parkinson’s
We are 100% committed to devoting the rest of our lives to improving the lives of people affected by Parkinson’s
Our Unique Business Model can be rolled out Worldwide with the right investment and backing
We also have experience working with multiple vendors
We possess strong planning and tracking skills
We are customer focused, well organised, detail oriented
We can demonstrate excellent time, priority, and self-management skills
Strong project-management skills
Effective leadership skills and proven ability to foster team productivity and cohesiveness.
Excellent communication skills with the ability to add value to your organisation from a Patient perspective
We have the proven ability to negotiate and influence others
- Acting as Parkinson’s Advocates
- Advisors on problems in Parkinson’s
- Bid writing for funding purposes
- Design of questionnaires
- Organising focus groups
- UX design
- Report writing
- Public Speaking
- Creating Awareness at Corporate Events
- Partnering with organisations who can make a difference
What type of impact can we make?
Our unique business model offers experience, talents and a perspective which can make a vital contribution to innovative products & research methods that the Medical industry are developing for Parkinson’s. Therefore, we can take part in improving the lives of people everywhere suffering from this incurable disease. We want to be part of the change that is needed in order to accelerate finding a cure.
Let’s help the Medical industry to help us – The People with Parkinson’s
From drug discovery to commercialisation - we support the full spectrum.
Business Development and Licensing - Need support to acquire, divest or license a product or project? That's what we do. Regulatory Affairs, Pharmacovigilance - If you need support with your regulatory affairs, regulatory strategy or pharmacovigilance needs, we can arrange this through our trusted partner organisation. Wide Network - Projects at initial scientific concepts? Products at commercialisation and reimbursement stage? Our partners will help. Due Diligence and Auditing - Looking for support for due diligence, or auditing of partners? We can arrange all this.
Pneumagen is using its platform technology, GlycoTarge™, to develop glycan targeted carbohydrate binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer.
Pneumagen’s lead product, Neumifil™, is a first-in-class mCBM40 being developed for the universal treatment of Influenza Virus (IFV) and Respiratory Synctial Virus (RSV) infections. When administered intranasally in preclinical models, Neumifil™ has demonstrated prevention, treatment and post-exposure prophylaxis of IFV infection with no observed toxicity. Pneumagen’s mCBM, in development for cancer, isknown as Neumonco™. In vitro data have demonstrated that mCBMs target and enter cancer cells, reducing cell proliferation, migration, metabolism and differentiation.
Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilities in glycobiology. Please visit www.pneumagen.com for more information.
Precision for Medicine, Oncology & Rare Disease
Precision for Medicine, Oncology and Rare Disease is proud to offer the first comprehensive, fully integrated clinical development solution. We are devoted exclusively to oncology and rare disease, and our teams are passionate about improving the lives of these patients. By combining the progressive science of biomarkers and analytics with our excellence in complex clinical trial execution, we help innovators to invest wisely, discover value sooner and optimize the returns from research.
Contact Precision for Medicine, Oncology and Rare Disease via their website
Redx Pharma discovers and develops proprietary, small molecule drugs to address areas of high unmet medical need in cancer and fibrosis. In cancer, we pursue targeted therapies where a biomarker can potentially be used for selecting those patients that are most likely to benefit from therapy, and/or drugs that are designed to disrupt cancer resistance pathways. In fibrosis, we are focused on developing treatments that will stop and reverse the formation of fibrotic tissue. In both therapeutic areas we aim to develop drugs whose profile suggests they will be best in class, if not first in class.
Sareum is a drug discovery and development company, headquartered in Cambridge UK, that produces targeted small molecule therapeutics, focusing on cancer and autoimmune disease. Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.
Sareum operates an outsourced research model, working with collaborators (SRI International, the CRT Pioneer Fund and Hebei Medical University Biomedical Engineering Center) and a world-wide network of research providers. Its research pipeline includes two programmes undergoing pre-clinical IND-enabling studies.
Sekisui Diagnostics, a global provider of innovative medical diagnostics to physicians and laboratories, has been committed to improving the lives of patients for over 30 years. We continue to invest in new diagnostic products in the areas of diabetes, infectious disease, coagulation, diagnostic enzymes and automated systems. We are a leading provider of rapid tests in the U.S., and high throughput coagulation systems in Japan. We develop, manufacture, and supply over 1.7 billion tests each year to the global healthcare market through direct sales, our commercial distribution networks and our partners.
Selcia Ltd is a leading provider of contract research services in drug discovery and 14C radiolabelling. In January 2018 Selcia became part of Eurofins Pharma Discovery Services affording Selcia the capacity to deliver extensive and seamless solutions and services that span the whole spectrum of drug discovery.
Selcia Drug Discovery focusses on integrated small molecule drug discovery, with a strong track record of IP generation and preclinical candidate delivery for customers – 25 patents and 11 preclinical candidates generated. USPs are the medicinal chemistry of macrocycles, and a peptidyl prolyl isomerase (PPIase) screening platform.
Selcia radiolabelling specialises in 14C GMP radiolabelling, producing 14C radiolabelled compounds for a global customer base encompassing both the life sciences and chemical industries. Applications of the radiolabelled products prepared by Selcia include: preclinical and clinical drug metabolism studies; mass balance, IV microdosing, dermal penetration, regulatory and environmental fate studies.
Selcia also offers GLP NMR and mass spectrometry services to support regulatory submissions, and specialised purification capabilities from analytical (µg) to multi-100g scale.
Areas of Expertise:
• Medicinal chemistry: Tool compounds; peptides; macrocycles; natural product chemistry
• Biology: Assay development; ADME screens; PPIase profiling
• Disease expertise: Anti-infectives; inflammation; CNS; pain; metabolic; oncology & ophthalmology
• Target classes: GPCRs; ion channels; enzymes; protein-protein interactions
• 14C Custom Radiosynthesis
• GMP 14C Radiolabelled API for Clinical Trials
• GLP/GMP Analytics – GLP NMR
• Metabolites and Impurities (Profiling and Synthesis), standards and stable labelled compounds